Please check your internet connection and try again.
# زولبيديم (Zolpidem)
## Overview
Zolpidem is a non-benzodiazepine hypnotic agent (Z-drug) that acts as a selective agonist at the benzodiazepine receptor subtype 1 (omega-1) of the $GABA_A$ complex. It is classified as a Schedule IV controlled substance due to potential for dependency and abuse.
## Primary Indications
Short-term treatment of insomnia characterized by difficulties with sleep initiation.
## Adult Dosing
* **Immediate-release:** 5 mg (women/elderly) or 5–10 mg (men) taken immediately before bedtime; 10 mg is the absolute maximum daily dose.
* **Extended-release:** 6.25 mg (women/elderly) or 12.5 mg (men) taken immediately before bedtime; 12.5 mg is the absolute maximum daily dose.
* **Sublingual (Intermezzo):** 1.75 mg (women/elderly) or 3.5 mg (men) used only for middle-of-the-night awakening if at least 4 hours of sleep remain.
## Pediatric Dosing
**Not indicated.** Safety and efficacy have not been established in pediatric patients (<18 years). Use is generally contraindicated in this population.
## Dose Adjustments
* **Hepatic Impairment:** Reduce dose; 5 mg immediate-release is the standard starting dose. Use with caution.
* **Geriatric/Debilitated:** Utilize lowest possible dose (5 mg IR or 6.25 mg ER) due to increased sensitivity and risk of falls/cognitive impairment.
* **Concurrent CNS Depressants:** Reduce dose if co-administered with other CNS depressants.
## Contraindications
* Known hypersensitivity to zolpidem.
* History of complex sleep behaviors (e.g., sleep-driving, eating, or engaging in other activities while not fully awake).
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Drowsiness, dizziness, headache, diarrhea, "drugged" feeling.
* **Serious:** Complex sleep behaviors (hallucinations, sleep-walking, sleep-driving), severe anaphylaxis, depression/suicidal ideation, respiratory depression, complex allergic reactions (angioedema).
## Key Drug Interactions
* **CNS Depressants (Opioids, alcohol, benzodiazepines):** Profound additive sedation and risk of respiratory depression.
* **CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin):** Increase zolpidem levels significantly; avoid or reduce dose.
* **CYP3A4 Inducers (e.g., rifampin, St. John’s Wort):** May reduce efficacy.
* **SSRIs/SNRIs:** Increased risk of somnolence.
## Monitoring
* Monitor for signs of CNS impairment the following morning.
* Assess for misuse, abuse, or development of complex sleep behaviors.
* Evaluate persistent insomnia if symptoms do not remit after 7–10 days.
## Clinical Pearls
* **Timing:** Administer only immediately before going to bed. Avoid administration if the patient cannot stay in bed for a full 7–8 hours.
* **The "Next-Day" Risk:** FDA-mandated dose reductions for women were established due to slower clearance and higher morning plasma concentrations, increasing risk of impaired driving.
* **Tapering:** While not always required for short-term use, abrupt discontinuation may cause withdrawal-like symptoms (nausea, vomiting, flushing, abdominal cramps) if used long-term (off-label).
***
**Disclaimer:** This information is for educational purposes only. Clinical practice and regional protocols may vary. Please verify current prescribing information, dosage calculations, and safety alerts against institutional guidelines and the most recent package insert before administration.
